Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.

J Weiss, Glen; R Infante, Jeffrey; Gabriela Chiorean, E; J Borad, Mitesh; C Bendell, Johanna; R Molina, Julian; Tibes, Raoul; K Ramanathan, Ramesh; Lewandowski, Karen; F Jones, Suzanne; E Lacouture, Mario; K Langmuir, Virginia; Lee, Hank; Kroll, Stew; A Burris, Howard

doi:10.1158/1078-0432.ccr-10-3425

Public

Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.

Published in Clinical cancer research : an official journal of the American Association for Cancer Research • May 1, 2011

NobleIDark:/48914/w1/20260526/172E0B87Record on NobleID

Authors:

Glen J Weiss

,

Jeffrey R Infante

,

E Gabriela Chiorean

Abstract

PURPOSE: The objectives of this phase 1, first-in-human study were to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), safety, pharmacokinetics, and preliminary activity of the hypoxia-activated prodrug TH-302 in patients with advanced solid tumors. EXPERIMENTAL DESIGN: TH...

Discussions